cas 1297537-45-1|| where to buy 3-Acetyl-1H-pyrazole-5-carboxylic acid

Produktname:3-Acetyl-1H-pyrazole-5-carboxylic acid

IUPAC Name:3-acetyl-1H-pyrazole-5-carboxylic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM281127-5g	in stock	Ȁư
CM281127-25g	in stock	ƄŢƞ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1297537-45-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1297537-45-1; Molekulare Formel:C6H6N2O3; Schmelzpunkt:-; SMILES-Code:O=C(C1=CC(C(C)=O)=NN1)O; Dichte:

: Katalognummer:CM281127; Molekulargewicht:154.13; Siedepunkt:; Mdl-Nr.:MFCD05864511; Lagerung:Store at 2-8°C.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Darolutamide; Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.